Publications by authors named "Sebastian Bergler"
Cytochrome P450 2E1 (CYP2E1)-associated reactive oxygen species production plays an important role in the development and progression of inflammatory liver diseases such as alcoholic steatohepatitis. We developed two new inhibitors for this isoenzyme, namely 12-imidazolyl-1-dodecanol (I-ol) and 1-imidazolyldodecane (I-an), and aimed to test their effects on non-alcoholic steatohepatitis (NASH). The fat-rich and CYP2E1 inducing Lieber-DeCarli diet was administered over 16 weeks of the experimental period to induce the disease in a rat model, and the experimental substances were administered simultaneously over the last four weeks.
View Article and Find Full Text PDFCytochrome P450 2E1 (CYP2E1) is a key target protein in the development of alcoholic and nonalcoholic fatty liver disease (FLD). The pathophysiological correlate is the massive production of reactive oxygen species. The role of CYP2E1 in the development of hepatocellular carcinoma (HCC), the final complication of FLD, remains controversial.
View Article and Find Full Text PDFArticle Synopsis
- Alcoholic steatohepatitis (ASH) is a liver disease caused by chronic alcohol consumption, potentially leading to severe health issues like liver dysfunction and cancer.
- A new study developed two promising drug candidates, I-ol and I-an, which effectively inhibit the enzyme CYP2E1, improving liver health in alcohol-consuming rats.
- These new drugs offer a better treatment option for ASH compared to existing medications, making them a potential breakthrough in liver disease management.